Incretin Atlas › Trials › REIMAGINE 5 (vs tirzepatide 5 mg)
REIMAGINE 5 (vs tirzepatide 5 mg)
CagriSema · t2d
Design
- Molecule(s)
- CagriSema
- Population
- t2d
- Official title
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
- Sponsor
- Novo Nordisk A/S
- Phase
- 3
- Registry status
- completed · 2024-11 → 2026-06
- Participants
- 1023
- Duration
- 60 weeks
- Registry
- NCT06534411
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CagriSema 1.0/1.0 mg vs tirzepatide 5 mg (active) | t2d | 60 | — | −12.4 % | — | −1.7 | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- CagriSema 1.0/1.0 mg: Head-to-head vs tirzepatide 5 mg: weight −9.1 %, HbA1c −1.67 %-points (efficacy estimand); HbA1c non-inferior.
Verbatim quotes from the source (2)
- CagriSema 1.0/1.0 mg · weight_eff · company announcement
CagriSema 1.0 mg/1.0 mg was superior to tirzepatide 5 mg for weight loss
- CagriSema 1.0/1.0 mg · hba1c · company announcement
1.71% (CagriSema) vs. 1.67% (tirzepatide) – non-inferior
Primary sources
- Novo Nordisk. CagriSema REIMAGINE 5 and REDEFINE 9 topline results [company announcement]. 2026 Sep 21. Available from: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916774
- ClinicalTrials.gov NCT06534411
How to cite this page
Medical Adviser's Group. Incretin Atlas: REIMAGINE 5 (vs tirzepatide 5 mg). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/reimagine-5/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.